The efficacy of erythropoietin mouthwash in prevention of oral mucositis in patients undergoing autologous hematopoietic SCT: A double-blind, randomized, placebocontrolled trial

Hosseinjani, H. and Hadjibabaie, M. and Gholami, K. and Javadi, M. and Radfar, M. and Jahangard-Rafsanjani, Z. and Hosseinjani, E. and Shabani, N. and Vaezi, M. and Ghavamzadeh, A. (2017) The efficacy of erythropoietin mouthwash in prevention of oral mucositis in patients undergoing autologous hematopoietic SCT: A double-blind, randomized, placebocontrolled trial. Hematological Oncology, 35 (1). pp. 106-112.

[img] Text
The efficacy of erythropoietin mouthwash in prevention of.pdf

Download (149kB)


Oral mucositis (OM) as a complication of high-dose chemotherapy is frequently occurred in hematopoietic stem cell transplantation (HSCT) settings. Erythropoietin (EPO) has anti-inflammatory, antioxidant andwound-healing properties and therefore could have an important role in the prevention of OM. We conducted a double-blind, randomized, placebocontrolled trial to evaluate the EPO mouthwash effect onOMincidence and severity in 80 patients with non-Hodgkin’s lymphoma, Hodgkin disease (HD) or multiple myeloma, undergoing autologous hematopoietic stem cell transplantation. Patients received either EPO mouthwash (50IU/ml, 15ml four times a day) (n = 40) or placebo (n = 40) from the starting day of high-dose chemotherapy until day +14 after transplantation or until the day of discharge from the hospital, whichever occurred first. OM was evaluated daily for 21 days after transplantation or until resolution ofOMaccording toWorld Health Organization oral toxicity scale. The incidence of OM (grades 1–4) in the EPO mouthwash group and control group was significantly different (27.5 vs 77.5, p<0.001). The mean ± SD of two other parameters of OM including maximum intensity OM score (0.60 ± 1.06 vs 1.67± 1.27) and average intensity OM score (0.47± 0.80 vs 1.28 ± 0.86) was significantly lower in the intervention group (p<0.001).Moreover, themean± SD duration ofOMwas also significantly shorter among the EPO mouthwash recipients (1.92± 3.42 days vs 5.42 ± 3.86 days, P<0.001). Also, the duration of neutropenic fever was significantly shorter in the intervention group (2.12 ± 2.42 days vs 3.95± 4.01days, p = 0.016). It is concluded that EPO mouthwash can reduce the incidence and duration of OM. © 2015 John Wiley & Sons, Ltd.

Item Type: Article
Additional Information: Cited By :9 Export Date: 16 February 2020 CODEN: HAOND Correspondence Address: Hadjibabaie, M.; Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical SciencesIran; email:
Uncontrolled Keywords: EPO mouthwash Hematopoietic SCT High-dose chemotherapy Oral mucositis aciclovir carboplatin chlorhexidine cotrimoxazole cytarabine erythropoietin etoposide fluconazole melphalan mouthwash nystatin placebo povidone iodine adult Article autologous hematopoietic stem cell transplantation cancer combination chemotherapy controlled study disease severity double blind procedure drug efficacy drug megadose febrile neutropenia female fever Hodgkin disease human incidence major clinical study male multiple myeloma nonhodgkin lymphoma Pneumocystis jiroveci pneumocystosis priority journal prospective study randomized controlled trial transplantation conditioning adverse effects complication hematopoietic stem cell transplantation Lymphoma, Non-Hodgkin middle aged stomatitis treatment outcome wound healing Double-Blind Method Humans Mouthwashes
Subjects: WU Dentistry. Oral surgery
QV pharmacology
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib3 lib3
Date Deposited: 28 Apr 2020 08:11
Last Modified: 28 Apr 2020 08:11

Actions (login required)

View Item View Item